Quarterly Cashflow and Activities Report (ASX Announcement)

Jul 30th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2021.

Read More

Lynda Cheng appointed as non-executive director (ASX Announcement)

Jul 28th, 2021

Melbourne, Australia; 28 July 2021: Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Ms Lynda Cheng as an independent non-executive director, effective 1 August 2021.   ... Ms Cheng has more than 25 years of experience as a finance executive including more than 15 years at Visy Industries/Pratt... Read More

Starpharma to present DEP® platform at CRS Annual Meeting (ASX Announcement)

Jul 27th, 2021

Melbourne, Australia; 27 July 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has been invited to present at the prestigious Controlled Release Society (CRS) Virtual Annual Meeting. Starpharma will be represented by its VP of Research, Dr David Owen, who will present an overview of the DEP® platform and its benefits as part of the ‘Success Stories from Bench... Read More

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant (ASX Announcement)

Jul 27th, 2021

Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.

Read More

TGA infringement notices for alleged advertising (ASX Announcement)

Jul 5th, 2021

Starpharma today announces it has received several infringement notices from the TGA with respect to alleged advertising of VIRALEZE™ antiviral nasal spray to Australian consumers.

Read More

Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 24th, 2021

Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.

Read More

VIRALEZE UK update (ASX Announcement)

Jun 21st, 2021

Starpharma advises that its UK retail partner, LloydsPharmacy, has received correspondence from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in relation to specific promotional claims made for VIRALEZE™ antiviral nasal spray.

Read More

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.

Read More

Latest Testing Confirms Viraleze Highly Effective Against Alpha, Beta and Gamma COVID Variants

Jun 18th, 2021

News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here

Read More

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

Jun 18th, 2021

"New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus," as reported by the New Delhi Times. Read the full article here.

Read More

Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

Jun 18th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants," The Market Herald reports. Read the full article here.

Read More

VIRALEZE SPL7013 virucidal against multiple COVID variants (ASX Announcement)

Jun 18th, 2021

Starpharma today released new data demonstrating that SPL7013, the active in VIRALEZE antiviral nasal spray, achieved more than 99.9% reduction of virus against the Alpha (UK), Beta (South Africa) and Gamma (Japan/Brazil) SARS-CoV-2 coronavirus ‘Variants of Concern’ in laboratory-based virucidal assays.

Read More

VIRALEZE antiviral nasal spray registered for sale in India (ASX Announcement)

Jun 11th, 2021

Starpharma today announced it had received confirmation that VIRALEZE antiviral nasal spray has been registered for sale nationally in India via the Central Drugs Standard Control Organisation (CDSCO), which is part of the Indian Ministry of Health and Family Welfare.

Read More

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Jun 1st, 2021

Markets Insider featured Viraleze and Starpharma following the announcement of SPL7013's potent antiviral activity against the UK coronavirus variant. Read the full article here

Read More

Starpharma (ASX:SPL)'s nasal spray achieves 98% efficacy against COVID-19

Jun 1st, 2021

"Biopharmaceutical company Starpharma (ASX:SPL) claims the company’s nasal spray product is a highly efficacious means of protection from the UK variant of the coronavirus," Finance News Network reports. Read the full article here

Read More

Starpharma (ASX:SPL) shows 98pc antiviral activity against U.K COVID-19 variant

Jun 1st, 2021

The Market Herald reports on Starpharma's latest announcement: "Starpharma (SPL) has confirmed that its SPL7013 drug has potent antiviral activity against the U.K. SARS-CoV-2 variant.

"In laboratory studies, SPL7013 achieved a reduction of more than 98 per cent against the virus."

Read the full article here. 

Read More

VIRALEZE SPL7013 highly active in UK variant of coronavirus (ASX Announcement)

Jun 1st, 2021

Starpharma today announced new data confirming that SPL7013, the active in VIRALEZE antiviral nasal spray, has potent antiviral activity against the UK (B.1.1.7) SARS-CoV-2 variant of concern (hCoV-19/England/204820464/2020) in laboratory studies, achieving more than 98% reduction in infectious virus in antiviral assays.

Read More

Tackling Covid: How the Harlequins are defending themselves

May 22nd, 2021

Twickenham Nub News interviewed Harlequins’ Head of Medical Services, Mike Lancaster, about the partnership with Viraleze. "The Harlequins’ long-awaited return to Twickenham Stoop has seen the team make many changes to ensure players’ safety.

"Alongside several changes at the stadium, the team has also started defending itself with a new nose spray, Viraleze." Read the full article here. 

Read More

Tax incentives to encourage innovation

May 18th, 2021

Dr Jackie Fairley, CEO of Starpharma discusses the Australian governments proposals for a 'patent box' and what it will mean for the company and Australian innovation in general. Watch here. (ausbiz account required)

Read More

Harlequins Partners with Anti-Viral Nasal Spray Viraleze

May 11th, 2021

Sport Industry Group featured the announcement of Starpharma's VIRALEZETM partnership with Harlequins. "Harlequins has announced a new partnership with antiviral nasal spray VIRALEZETM, which the club says it will use as one part of its suite of measures put in place to help protect its players and coaching staff." Read more here.

Read More

Harlequins Partners Antiviral Nasal Spray Brand Viraleze

May 11th, 2021

iSportconnect reported on the new partnership between Starpharma's antiviral nasal spray, VIRALEZETM, and Harlequins, a professional rugby union team in the UK. Read more here

Read More

VIRALEZE™ partners with Harlequins in the UK (ASX Announcement)

May 11th, 2021

Starpharma attaches a media release announcing the partnership between VIRALEZE™ and Harlequins in the UK, which was distributed today. (Click here)

Harlequins is a professional English rugby union team, established in 1866, and one of the founding members of the Rugby Football Union. Harlequins play in the English Premiership, the top level of English rugby union. The Club’s home ground is the Twickenham Stoop Stadium, “The Stoop”, in south-west London. For more information about Harlequins, visit www.quins.co.uk.

 

Read More

Starpharma (ASX:SPL) launches antiviral nasal spray in Europe

May 6th, 2021

The Market Herald reported on Starpharma's launch of VIRALEZE™  in Europe. Read the full article here.

  • Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store
  • VIRALEZE is a broad spectrum antiviral nasal spray, which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute
  • The product is already available online in the U.K. and through Lloyds Pharmacy’s 1400 stores, with the company now pursuing avenues to provide rapid access for VIRALEZE in India
  • Starpharma shares are up 3.93 per cent, trading at $1.85

 

Read More

VIRALEZE™ launches in Europe (ASX Announcement)

May 6th, 2021

Starpharma today announced that VIRALEZE antiviral nasal spray is now available for purchase by consumers in Europe via Starpharma’s www.viraleze.co webstore.

Read More

Australian company develops a $27 anti-viral nasal spray that 'deactivates' Covid - and it's being used right across the UK

May 4th, 2021

Eliza McPhee for Daily Mail Australia reported: An Australian biotech company has joined the fight against coronavirus by launching an anti-viral nasal spray that's already available in the UK. Read the article here

  • Biotech company Starpharma has launched anti-viral nasal spray in the UK
  • It acts as a barrier to coronavirus, trapping it in the nose and inactivating virus
  • Spray best used once every six hours for up to 30 days, CEO Jackie Fairley says
  • Melbourne-based company says it has plans to launch product soon in Australia 
Read More

Starpharma (ASX:SPL) spends March quarter developing VIRALEZE

Apr 28th, 2021

Starpharma featured in The Market Herald following the announcement of Starpharma's Quarterly Cashflow and Activities Report. Read more here

Read More

Shareholder Newsletter

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Read More

Quarterly Cashflow and Activities Report

Apr 27th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2021.

Read More

GlaxoSmithKline hoping to deliver Australia’s next COVID treatment

Apr 16th, 2021

Starpharma featured in The Sydney Morning Herald's daily COVID-19 update, as reported by Emma Koehn: ASX-listed companies have pivoted swiftly towards virus treatments and preventative in the past year, including Melbourne-based Starpharma which successfully brought a nasal spray to market in the UK last month. Read more here

Read More

Aussie virus killer not to be sneezed at

Apr 11th, 2021

The Australian interviewed Dr Jackie Fairley, Starpharma CEO, about the recent launch of Viraleze in the UK. "As the nation hyperventilates over a delay in the vaccine rollout, Starpharma is rolling out a new line of defence against the coronavirus in global markets." Read more here. (Behind paywall)

Read More

LloydsPharmacy launches nasal spray designed to fight coronavirus

Mar 30th, 2021

The Grocer reported on the launch of VIRALEZE in LloydsPharmacy across the UK. It launches online this week, ahead of an in-store rollout from April. Read more here.

Read More

Covid antiviral nasal spray available from Lloyds

Mar 30th, 2021

Pharmacy Magazine UK reported on the launch of VIRALEZE in the UK. A novel nasal spray available exclusively from LloydsPharmacy. The UK will be the first country to launch this product. Read more here.

Read More

Lloyds Pharmacy offering first-ever Covid nasal spray Viraleze that 'blocks 99.9% of germs'

Mar 30th, 2021

CambridgeshireLive featured news of the VIRALEZE launch in the UK. A groundbreaking Covid nasal spray called Viraleze is now available to buy online. Lloyds Pharmacy is rolling out the UK's first-ever nasal spray specifically designed to fight coronavirus. Read more here

Read More

VIRALEZE™ now launched by LloydsPharmacy in the UK

Mar 30th, 2021

Starpharma today confirms that Starpharma’s VIRALEZE™ antiviral nasal spray has launched in the UK by LloydsPharmacy, as announced on 25 March 2021.

Read More

VIRALEZE™ featured on Sky News

Mar 29th, 2021

Sky News interviewed Starpharma CEO Dr Jackie Fairley upon launch of VIRALEZE™ at LloydsPharmacy in the UK. Dr George Kinghorn, Infectious Disease Adviser and former Clinical Director of the Sheffield Teaching Hospitals NHS Foundation Trust was also interviewed for further commentary on VIRALEZE™.

 

Read More

Starpharma to launch anti-COVID nasal spray with major UK pharmacy chain

Mar 25th, 2021

Business News Australia reported VIRALEZE will be stocked by LloydsPharmacy in the UK. It will first be made available at LloydPharmacy's online store and is expected to be instore in April. Read more here.

Read More

Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain

Mar 25th, 2021

The Age reported Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown. Read more here

Read More

VIRALEZE™ to be launched with LloydsPharmacy in the UK

Mar 25th, 2021

Starpharma today announced it has signed a sales and distribution agreement for VIRALEZE™ antiviral nasal spray with LloydsPharmacy and the McKesson group in the UK. LloydsPharmacy/McKesson is one of the largest pharmacy groups in the UK and is also a major wholesaler in the UK.

Read More

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Mar 16th, 2021

Finance News Network reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model. Read more here

Read More

Starpharma (ASX:SPL) shares rise on breast cancer development

Mar 16th, 2021

The Market Herald reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, had achieved anti-cancer activity in breast cancer, and that the drug outperformed Herceptin, a treatment for a type of breast cancer called HER2 positive. Read more here

Read More

DEP® HER2-lutetium outperforms in human breast cancer model

Mar 16th, 2021

Starpharma today announced that its second radiopharmaceutical candidate, DEP® HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin® (trastuzumab) labelled with lutetium, in a human breast cancer model (BT474).

Read More

SPL7013 active against other pandemic coronaviruses

Mar 3rd, 2021

Starpharma today announces new data from The Scripps Research Institute in the US and other specialist laboratories on the activity of SPL7013 against important respiratory viruses, including those responsible for past pandemics. This new data further confirms the broad spectrum antiviral properties of SPL7013 (VIRALEZE™ active), with SPL7013 blocking the spike protein of two additional important pandemic causing coronaviruses, SARS-CoV and MERS‑CoV.

Read More

Starpharma Up With News, Down With None; Timing Entry Makes Sense

Feb 25th, 2021

Seeking Alpha, a financial market portal featured an update Starpharma, including the European registration of its VIRALEZE™ antiviral nasal spray. To read the full article click here.

Read More

Interim Report and Half-Year Financial Results

Feb 25th, 2021

Starpharma today released its interim report and financial results for the half-year ended 31 December 2020.

Read More

Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23rd, 2021

Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here

Read More

VIRALEZE™ antiviral nasal spray registered in Europe

Feb 23rd, 2021

Starpharma announced today it had received confirmation that the VIRALEZE™ antiviral nasal spray has been successfully registered for sale in Europe, including in the UK.

Read More

Starpharma signs research agreement with MSD

Feb 12th, 2021

The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here

Read More

Starpharma signs DEP® ADC Research Agreement with MSD

Feb 12th, 2021

Starpharma today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.

 

Read More

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 10th, 2021

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.

 

Read More